{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:55:16Z","timestamp":1788501316784,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Cancer Institute in testing ascorbate in the NCI-60 cell panel"},{"name":"Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Free Radical Biology and Medicine"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.freeradbiomed.2015.06.032","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T10:21:56Z","timestamp":1435314116000},"page":"193-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model"],"prefix":"10.1016","volume":"87","author":[{"given":"Oscar K.","family":"Serrano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nermi L.","family":"Parrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Christian","family":"Violet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Zornjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Basseville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib1","article-title":"Cancer Statistics, 2014","author":"Siegel","year":"2014","journal-title":"CA Cancer J. Clin"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib5","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib7","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjd.12238","article-title":"A costly revolution for a subgroup of patients with metastatic melanoma","volume":"168","author":"van Akkooi","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib8","first-page":"1694","article-title":"Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations","volume":"367","author":"Flaherty","year":"2012"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/path.4318","article-title":"Molecular and genetic diversity in the metastatic process of melanoma","author":"Harbst","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib10","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1758834012466280","article-title":"Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm","volume":"5","author":"Khattak","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib11","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.1999.17.9.2745","article-title":"Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma","volume":"17","author":"Chapman","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/CMR.0b013e3283457743","article-title":"J. Dacarbazine-based chemotherapy as first-line treatment in noncutaneous metastatic melanoma: multicenter, retrospective analysis in Asia","volume":"21","author":"Yi","year":"2011","journal-title":"Melanoma Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib13","first-page":"21","article-title":"Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview","volume":"19","author":"Serrone","year":"2000","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib14","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1089\/ars.2013.5372","article-title":"Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics","volume":"19","author":"Parrow","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.freeradbiomed.2009.02.016","article-title":"Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects","volume":"47","author":"Verrax","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.freeradbiomed.2009.04.001","article-title":"Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment","volume":"47","author":"Levine","year":"2009","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib17","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.freeradbiomed.2011.03.007","article-title":"Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer","volume":"50","author":"Espey","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib18","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00280-013-2070-8","article-title":"J. Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial","volume":"71","author":"Welsh","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib19","doi-asserted-by":"crossref","first-page":"e29794","DOI":"10.1371\/journal.pone.0029794","article-title":"Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"7","author":"Monti","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib20","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.1073\/pnas.0702854104","article-title":"Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo","volume":"104","author":"Chen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib21","doi-asserted-by":"crossref","first-page":"11105","DOI":"10.1073\/pnas.0804226105","article-title":"Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice","volume":"105","author":"Chen","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1667\/RR1375.1","article-title":"The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells","volume":"170","author":"Frankenberg-Schwager","year":"2008","journal-title":"Radiat. Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib23","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1084\/jem.20112398","article-title":"Chemokine-dependent T cell migration requires aquaporin-3-mediated hydrogen peroxide uptake","volume":"209","author":"Hara-Chikuma","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib24","first-page":"21","article-title":"B16 as a mouse model for human melanoma. Curr. Protoc. Immunol","volume":"20","author":"Overwijk","year":"2001","journal-title":"Unit"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0003-2697(89)90243-1","article-title":"Ascorbic acid analysis using high-performance liquid chromatography with coulometric electrochemical detection","volume":"181","author":"Washko","year":"1989","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib26","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/nprot.2006.339","article-title":"Clonogenic assay of cells in vitro","volume":"1","author":"Franken","year":"2006","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib27","first-page":"23","article-title":"Wound-healing assay","volume":"294","author":"Rodriguez","year":"2005","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib28","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/0003-4819-140-7-200404060-00010","article-title":"Vitamin C pharmacokinetics: implications for oral and intravenous use","volume":"140","author":"Padayatty","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib30","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1749-6632.2002.tb02920.x","article-title":"Oxygen, oxidants, and antioxidants in wound healing: an emerging paradigm","volume":"957","author":"Sen","year":"2002","journal-title":"Ann. N. Y. Acad. Sci"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib31","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4049\/jimmunol.154.1.180","article-title":"Multiple defects in innate and adaptive immunologic function in NOD\/LtSz-scid mice","volume":"154","author":"Shultz","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib32","doi-asserted-by":"crossref","first-page":"3290","DOI":"10.1073\/pnas.89.8.3290","article-title":"The nonobese diabetic scid mouse: model for spontaneous thymomagenesis associated with immunodeficiency","volume":"89","author":"Prochazka","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1158\/1078-0432.CCR-11-0946","article-title":"Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma","volume":"18","author":"Landreville","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bbrc.2011.02.035","article-title":"Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress","volume":"406","author":"Mercado","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/sj.bjc.6604817","article-title":"A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma","volume":"100","author":"Rocca","year":"2009","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10549-006-9392-8","article-title":"MDA-MB-435 cells are derived from M14 melanoma cells\u2014a loss for breast cancer, but a boon for melanoma research","volume":"104","author":"Rae","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/284629a0","article-title":"Vitamin C preferential toxicity for malignant melanoma cells","volume":"284","author":"Bram","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib38","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0891-5849(89)90160-3","article-title":"On the participation of higher oxidation states of iron and copper in Fenton reactions","volume":"6","author":"Sutton","year":"1989","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib39","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1006\/abbi.1993.1074","article-title":"The pecking order of free radicals and antioxidants: lipid peroxidation, alpha-tocopherol, and ascorbate","volume":"300","author":"Buettner","year":"1993","journal-title":"Arch. Biochem. Biophys"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib40","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/annonc\/mdn377","article-title":"Phase I clinical trial of i.v. ascorbic acid in advanced malignancy","volume":"19","author":"Hoffer","year":"2008","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib41","doi-asserted-by":"crossref","first-page":"5955","DOI":"10.1038\/srep05955","article-title":"Extracellular iron diminishes anticancer effects of vitamin C: an in vitro study","volume":"4","author":"Mojic","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib42","doi-asserted-by":"crossref","first-page":"6675","DOI":"10.1182\/blood-2011-08-371849","article-title":"Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron","volume":"118","author":"Hod","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib43","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1158\/0008-5472.CAN-10-3498","article-title":"Intrinsic anticancer drug resistance of malignant melanoma cells is abrogated by IFN-beta and valproic acid","volume":"71","author":"Roos","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/FPC.0b013e3283307cd9","article-title":"Effect of DNA repair host factors on temozolomide or dacarbazine melanoma treatment in Caucasians","volume":"19","author":"Boeckmann","year":"2009","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib46","doi-asserted-by":"crossref","first-page":"222ra218","DOI":"10.1126\/scitranslmed.3007154","article-title":"High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib47","doi-asserted-by":"crossref","first-page":"13604","DOI":"10.1073\/pnas.0506390102","article-title":"Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues","volume":"102","author":"Chen","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib48","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/sj.onc.1207405","article-title":"Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines","volume":"23","author":"Melnikova","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib49","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1600-0560.2012.01915.x","article-title":"Misregulation of Rad50 expression in melanoma cells","volume":"39","author":"Avaritt","year":"2012","journal-title":"J. Cutan. Pathol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/35056049","article-title":"Chromosomal stability and the DNA double-stranded break connection","volume":"2","author":"van Gent","year":"2001","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0891-5849(95)02003-9","article-title":"Evidence for sensitisation of DNA to oxidative damage during isolation","volume":"20","author":"Finnegan","year":"1996","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib52","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1515\/hsz-2012-0311","article-title":"HIF mediated and DNA damage independent histone H2AX phosphorylation in chronic hypoxia","volume":"394","author":"Wrann","year":"2013","journal-title":"Biol. Chem."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib53","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1002\/jcp.24957","article-title":"DJ-1 protects breast cancer cells against 2'-benzoyloxycinnamaldehyde-induced oxidative stress independent of Nrf2","volume":"230","author":"Ismail","year":"2015","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.freeradbiomed.2015.06.032_bib54","doi-asserted-by":"crossref","first-page":"43150","DOI":"10.1074\/jbc.M507124200","article-title":"DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity","volume":"280","author":"Zhou","year":"2005","journal-title":"J. Biol. Chem."}],"container-title":["Free Radical Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584915003007?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0891584915003007?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:27:15Z","timestamp":1760203635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0891584915003007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":54,"alternative-id":["S0891584915003007"],"URL":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.032","relation":{},"ISSN":["0891-5849"],"issn-type":[{"value":"0891-5849","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antitumor effect of pharmacologic ascorbate in the B16 murine melanoma model","name":"articletitle","label":"Article Title"},{"value":"Free Radical Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.freeradbiomed.2015.06.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}